Citations

Clear

959 citation(s) found for "Service, F J".

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
Kumar, Shaji , Medhekar, Rohan , Pei, Huiling , Lefèbvre, Patrick , Kaila, Shuchita, He, Jianming , Lafeuille, Marie‐Hélène, Cortoos, Annelore, Londhe, Anil, Mavros, Panagiotis , Lin, Thomas S., Usmani, Saad Z. , Usmani, Saad , Jakubowiak, Andrzej

Mayo Clinic

The Oncologist | March 25, 2022 | Volume: 27 | Issue: 7 | Pages: e589-e596

10.1093/oncolo/oyac067 | PMID 35462406 Get It

Abstract Background Patients with high-risk, newly diagnosed multiple myeloma (HR-NDMM) who are ineligible for autologous stem cell transplant (ASCT) have limited first-line treatment options. Recent meta-analyses evaluating the impact of incorporating daratumumab in the backbone regimen on progression-free survival (PFS) have found mixed results in these patients. Materials and Methods A pooled analysis of patient-level data for ASCT-ineligible patients with HR-NDMM [ie, del(17p), t(4;14), t(14;16)] from the MAIA and ALCYONE trials; stratified by study identifier and adjusting for cytogenetic abnormality subtype, baseline performance status, International Staging System stage, myeloma type, and renal impairment; was conducted. Impact of daratumumab on PFS and rates of complete response or better (≥CR), minimal residual disease (MRD)-negative CR, very good partial response or better (≥VGPR), and overall response (ORR) was compared to control. Results Among 101 patients in the daratumumab and 89 patients in the control cohort, median follow-up was 43.7 months. Daratumumab reduced the risk of progression or death by 41% (adjusted hazard ratio for PFS [95% confidence interval (CI)] = 0.59 [0.41-0.85]) versus control. At 36 months, the estimated proportion of patients who did not progress and were still alive was 41.3% in the daratumumab and 19.9% in the control cohort. Rates of ≥CR (41.6% vs. 22.5%), MRD-negative CR (24.8% vs. 5.6%), ≥VGPR (75.2% vs. 46.1%), and ORR (92.1% vs. 74.2%) were higher for daratumumab versus control. Conclusion These findings demonstrate that incorporation of daratumumab in frontline treatment regimens reduced the risk of progression or death and improved response rates among ASCT-ineligible HR-NDMM patients.
Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance
Iovleva, Alina , Mustapha, Mustapha M. , Griffith, M. Patrick , Komarow, Lauren , Luterbach, Courtney , Evans, Daniel R. , Cober, Eric , Richter, Sandra S. , Rydell, Kirsten, Arias, César A. , Jacob, Jesse T. , Salata, Robert A. , Satlin, Michael J. , Wong, Darren , Tyne, Daria Van , Doi, Yohei , Bonomo, Robert A , van Duin, David , Cooper, Vaughn S , Van Tyne, Daria , Doi, Yohei , Jacob, Jesse T , Griffith, Marissa P., Arias, César A. , Bonomo, Robert A.

Mayo Clinic

mBio | March 21, 2022 | Volume: 13 | Issue: 2 | Pages: No page available

10.1128/mbio.02759-21 | PMID 35311529 Get It

Carbapenem-resistant Acinetobacter baumannii (CR Ab ) constitutes a major threat to public health. To elucidate the molecular and clinical epidemiology of CR Ab in the United States, clinical CR Ab isolates were collected along with data on patient characteristics and outcomes, and bacterial isolates underwent whole-genome sequencing and antibiotic susceptibility phenotyping.
Abstract 11386: Self-Service Analysis of Best Practice Alert Acknowledgement Comments as a Method for Evaluation Reveals Opportunities for Optimization of Clinical Decision Support for Patients with Prolonged QT Syndrome
Qian, Ray , Johnsen, Paul J., Ackerman, Michael J. , Bos, J. Martijn , Caraballo, Pedro J.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.11386 Get It

Introduction: The main goal of Clinical Decision Support (CDS) is to provide timely and useful information for providers to deliver high-quality and safe care. Issues, like alert fatigue and provider burnout are commonly cited as unintended consequences of the CDS systems. Herein, we describe leveraging electronic health record (EHR) self-service reporting tools to gain insights on a CDS rule designed to avoid providers from ordering QT-prolonging medication in patients with history of QT-prolongation. Methods: Our EHR (Epic) SlicerDicer reporting tool was used to identify the frequency of QT-prolongation Best Practice Advisory (BPA) triggerings from 1/1/2020 to 12/31/2020 across Mayo Clinic sites. Additionally, associated patient encounter and BPA-specific data were queried. Text from acknowledgement comments to the BPA were reviewed and central themes and comments were categorized. Epic Clarity Data Warehouse was queried to identify the BPA-triggering medications and frequencies. Comparisons of percent action taken on the BPA were compared internally to Mayo Clinic’s BPA benchmark, and with national benchmarks using Epic BestPractice Pulse dashboard. Results: A total of 17,538 BPAs of interest were triggered across the Mayo Clinic sites in 2020, of which 3,696 (20.1%) were acted upon through either monitoring or medication discontinuation. This is below Mayo Clinic’s median of 29.2% for inpatient BPAs and 45.6% BPAs for outpatient, but above the national median of 10% (IQR 6.1-13.1%) for inpatient and 10% (IQR 4.3-19.5%) for outpatient BPAs actioned upon. A total of 30 different medications triggered the BPA, with the most common being ondansetron (41.5%), amiodarone (11.3%), and haloperidol (10.1%). User comments were left on 2,382 orders (13.5%) that acknowledged the BPA, but provided argument to prescribe drug. Three most common themes identified from comments on overridden BPAs: patient previously tolerated medication (19.0%), QT interval not prolonged on recent ECG (14.2%), and patient on hospice care (5.2%). Conclusion: Analysis of free text comments of CDS can be and should be performed to reveal opportunities for further improvement of CDS. Providers should be encouraged to provide comments when encountering CDS interventions.
The efficacy of posterior wall isolation in atrial fibrillation ablation: A systematic review and meta‐analysis of randomized controlled trials
Kanitsoraphan, Chanavuth , Techorueangwiwat, Chol, Kewcharoen, Jakrin , Mekritthikrai, Raktham , Shah, Parthav , Masry, Hicham El , Kewcharoen, Jakrin , El Masry, Hicham , Kanitsoraphan, Chanavuth , Rattanawong, Pattara , Prasitlumkum, Narut

Mayo Clinic

Journal of Arrhythmia | March 18, 2022 | Volume: 38 | Issue: 3 | Pages: 275-286

10.1002/joa3.12698 | PMID 35785381 Get It

AbstractBackgroundPosterior wall isolation (PWI) is an emerging approach in atrial fibrillation (AF) ablation, yet its efficacy remains controversial. This is the first meta‐analysis of randomized controlled trials (RCT) to evaluate the efficacy of PWI in AF ablation.ObjectiveTo assess the efficacy of PWI in reducing atrial arrhythmia recurrence following initial AF ablation at long‐term follow‐ups when compared to conventional methods.MethodsWe conducted a literature search from inception through September 2021 in EMBASE and MEDLINE databases. We included RCTs that compared outcomes in PWI and conventional approaches of AF ablation. Data from each study were combined using the random‐effects, generic inverse variance method of DerSimonian and Laird to calculate odds ratio (OR), and 95% confidence interval (CI).ResultsEight RCT from 2009 to 2020, including 1024 AF patients, were included. PWI did not decrease overall atrial arrhythmias recurrence (RR 0.96, 95% CI:0.88–1.05, I2 = 31.6%, p‐value 0.393). However, the pooled analysis showed a significant decrease in AF recurrence in PWI compared to controlled approaches (RR 0.88, 95% CI:0.81–0.96, I2 = 48.2%, p‐value .004). In the subgroup analysis, PWI significantly decreased AF recurrence in the studies that included only persistent AF (RR = 0.89, 95% CI:0.80–0.98, I2 = 65.2%, p‐value .014). PWI significantly decreased AF recurrence when compared to PVI with roof line (RR 0.84, 95% CI 0.74–0.95, I2 0.00%, p‐value .008).ConclusionOur study suggests that adding PWI significantly decreased AF recurrence in patients with persistent AF compared to controlled approaches. It highlights the importance of considering PWI during the initial procedure in this patient population.
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH -wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON T
Tesileanu, C. Mircea S. , Wick, Wolfgang , Clément, Paul M. , Erridge, Sara , Vogelbaum, Michael A. , Nowak, Anna K. , Baurain, Jean‐François , Mason, Warren , Wheeler, Helen , Gill, Sanjeev , Griffin, Matthew, Rogers, Leland , Taal, Walter , Weller, Michael , McBain, Catherine , Linde, Myra E. van , Aldape, Kenneth , Jenkins, Robert B., Hoogstrate, Youri , Heer, Iris de , Atmodimedjo, Peggy N., Dubbink, Hendrikus J. , IJcken, Wilfred F. J. van , Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G. , Gorlia, Thierry, French, Pim J. , Bent, Martin J. van den , Sanson, Marc , Wick, Wolfgang , Clement, Paul M , Nowak, Anna K , Baurain, Jean-Francois , Wheeler, Helen , Chinot, Olivier L , Taal, Walter , Weller, Michael , Aldape, Kenneth , Kros, Johan M. , Wesseling, Pieter , von Deimling, Andreas , Hoogstrate, Youri , Dubbink, Hendrikus J , van IJcken, Wilfred F J , Golfinopoulos, Vassilis , French, Pim J , van den Bent, Martin J , Sanson, Marc , Brandes, Alba Ariela , Chinot, Olivier , Rudà, Roberta , Wesseling, Pieter , Deimling, Andreas von , Brouwer, Rutger W. W.

Mayo Clinic

Clinical Cancer Research | March 11, 2022 | Volume: 28 | Issue: 12 | Pages: 2527-2535

10.1158/1078-0432.ccr-21-4283 | PMID 35275197 Get It

Abstract Purpose: In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase–wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. Patients and Methods: From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Results: Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82–1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61–1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. Conclusions: In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.
Current approaches to management of newly diagnosed multiple myeloma
Goel, Utkarsh , Usmani, Saad Z. , Kumar, Shaji , Usmani, Saad

Mayo Clinic

American Journal of Hematology | March 2, 2022 | Volume: 97 | Issue: S1 | Pages: No page available

10.1002/ajh.26512 | PMID 35234302 Get It

AbstractMajor developments in the treatment of multiple myeloma (MM) over the past decade have led to a continued improvement in survival. Significant progress has been made with deeper and longer remissions seen with newer treatment approaches—both for induction as well as maintenance therapy. The treatment approach to MM is guided by several factors including patient age, frailty, comorbidities, eligibility for autologous stem cell transplantation (ASCT), and risk stratification into standard‐risk or high‐risk MM. High‐risk MM is defined by the presence of t(4;14), t(14;16), t(14;20), del (17p), TP53 mutation, or gain (1q). Transplant eligible patients should receive 4–6 cycles of induction followed by stem cell collection. Patients can then undergo ASCT, or continue induction therapy and shift to maintenance, delaying ASCT till first relapse. Transplant ineligible patients should receive induction therapy followed by maintenance. For induction therapy prior to ASCT, a proteasome inhibitor‐IMiD combination remains standard with monoclonal antibody‐based quadruplets preferred in high‐risk patients. Among transplant ineligible patients, those with standard‐risk MM should receive DRd continued until disease progression, while bortezomib containing regimens (VRd or VRd lite) can be considered for high‐risk patients. Finally, standard‐risk patients should receive lenalidomide maintenance after induction/ASCT, while proteasome inhibitor‐IMiD combinations should be used for high‐risk patients.
Quo vadis now: Beyond genomics to an era of personalised medicine
Rahman, Shamima , Baumgartner, Matthias R. , Patterson, Marc, Baumgartner, Matthias , Morava, Éva , Patterson, Marc C. , Peters, Verena , Zschocke, Johannes

Mayo Clinic

Journal of Inherited Metabolic Disease | March 1, 2022 | Volume: 45 | Issue: 2 | Pages: 129-131

10.1002/jimd.12487 | PMID 35229313 Get It

CONNECT: A pragmatic clinical trial testing a remotely provided linkage to service coordination after hospitalization for TBI
Bergquist, Thomas F. , Moessner, Anne M., Mandrekar, Jay , Ransom, Jeanine E. , Dernbach, Nicole L., Kendall, Kathryn S., Brown, Allen W.

Mayo Clinic

Brain Injury | February 22, 2022 | Volume: 36 | Issue: 2 | Pages: 147-155

10.1080/02699052.2022.2042601 | PMID 35192438 Get It

AAPM Medical Physics Practice Guideline 12.a: Fluoroscopy dose management
Fisher, Ryan , Berkowitz, Lindsey K., Christianson, Olav, Dave, Jaydev K. , DeWeese, Lindsay , Harris, Nichole, Jafari, Mary Ellen, Jones, A. Kyle , Kobistek, Robert J., Loughran, B, Marous, Loren, Miller, Donald L. , Schueler, Beth A. , Schwarz, Bryan C. , Springer, A., DeWeese, Lindsay , Schueler, Beth, Schwarz, Bryan C , Applegate, Kimberly E. , Wunderle, Kevin

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 17, 2022 | Volume: 23 | Issue: 3 | Pages: No page available

10.1002/acm2.13526 | PMID 35174964 Get It

Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration
Rivard, Léna , Friberg, Leif , Conen, David , Healey, Jeff S. , Berge, Trygve , Boriani, Giuseppe , Brandes, Axel , Calkins, Hugh , Camm, A. John , Espuny, Josep Lluis Clua , Collins, Ronan, Connolly, Stuart, Dagres, Nikolaos , Elkind, Mitchell S.V. , Engdahl, Johan, Field, Thalia S. , Glotzer, Taya V., Hankey, Graeme J. , Hills, Mellanie True , Johnson, Linda S.B. , Joung, Boyoung, Krieger, Derk, Løchen, Maja-Lisa, Madhavan, Malini, Mairesse, Georges H., Montaner, Joan , Rienstra, Michiel , Rosenqvist, Mårten, Sandhu, Roopinder K., Smyth, Breda, Stavrakis, Stavros , Gelder, Isabelle C. Van, Wang, Ji‐Guang , Freedman, Ben , Joung, Boyoung , Healey, Jeffrey S , Chen, Lin Y , Lluis Clua Espuny, Josep , Dagres, Nikolaos , Elkind, Mitchell S V , Field, Thalia S , Gersh, Bernard J , Hankey, Graeme J , Harbison, Joseph A , Haeusler, Karl G , True Hills, Mellanie , Johnson, Linda S B , Khairy, Paul , Kirchhof, Paulus , Lip, Gregory Y H , Montaner, Joan , Ntaios, George , Quinn, Terence J , Rienstra, Michiel , Schnabel, Renate B , Stavrakis, Stavros , Themistoclakis, Sakis , Wang, Ji-Guang , Freedman, Ben , Boriani, Giuseppe , Joung, Boyoung , Brandes, Axel , Rivard, Lena , Friberg, Leif , Conen, David , Berge, Trygve , Calkins, Hugh , Camm, Alan John , Collins, Ronan, Connolly, Stuart, Engdahl, Johan, Glotzer, Taya V., Krieger, Derk, Løchen, Maja-Lisa, Madhavan, Malini, Mairesse, Georges H., Rosenqvist, Mårten, Sandhu, Roopinder K., Smyth, Breda, Gelder, Isabelle C. Van

Mayo Clinic

Circulation | January 31, 2022 | Volume: 145 | Issue: 5 | Pages: 392-409

10.1161/circulationaha.121.055018 | PMID 35100023 Get It

Growing evidence suggests a consistent association between atrial fibrillation (AF) and cognitive impairment and dementia that is independent of clinical stroke. This report from the AF-SCREEN International Collaboration summarizes the evidence linking AF to cognitive impairment and dementia. It provides guidance on the investigation and management of dementia in patients with AF on the basis of best available evidence. The document also addresses suspected pathophysiologic mechanisms and identifies knowledge gaps for future research. Whereas AF and dementia share numerous risk factors, the association appears to be independent of these variables. Nevertheless, the evidence remains inconclusive regarding a direct causal effect. Several pathophysiologic mechanisms have been proposed, some of which are potentially amenable to early intervention, including cerebral microinfarction, AF-related cerebral hypoperfusion, inflammation, microhemorrhage, brain atrophy, and systemic atherosclerotic vascular disease. The mitigating role of oral anticoagulation in specific subgroups (eg, low stroke risk, short duration or silent AF, after successful AF ablation, or atrial cardiopathy) and the effect of rhythm versus rate control strategies remain unknown. Likewise, screening for AF (in cognitively normal or cognitively impaired patients) and screening for cognitive impairment in patients with AF are debated. The pathophysiology of dementia and therapeutic strategies to reduce cognitive impairment warrant further investigation in individuals with AF. Cognition should be evaluated in future AF studies and integrated with patient-specific outcome priorities and patient preferences. Further large-scale prospective studies and randomized trials are needed to establish whether AF is a risk factor for cognitive impairment, to investigate strategies to prevent dementia, and to determine whether screening for unknown AF followed by targeted therapy might prevent or reduce cognitive impairment and dementia.